Next Article in Journal
Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines
Next Article in Special Issue
Circulating Tumour Cell Biomarkers in Head and Neck Cancer: Current Progress and Future Prospects
Previous Article in Journal
p21cip1/waf1 Coordinates Autophagy, Proliferation and Apoptosis in Response to Metabolic Stress
Previous Article in Special Issue
Accuracy of Tumour-Associated Circulating Endothelial Cells as a Screening Biomarker for Clinically Significant Prostate Cancer
Open AccessReview

Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors

1
Section of Medical Pathophysiology, Food Science and Endocrinology, Dept. of Experimental Medicine, Sapienza University of Rome, 00165 Rome, Italy
2
Internal Medicine, Angioloni Hospital, San Piero in Bagno, 47026 Forlì-Cesena, Italy
3
Endocrinology Unit, Regina Elena National Cancer Institute IRCCS, 00144 Rome, Italy
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(8), 1113; https://doi.org/10.3390/cancers11081113
Received: 3 July 2019 / Revised: 31 July 2019 / Accepted: 2 August 2019 / Published: 4 August 2019
(This article belongs to the Special Issue New Biomarkers in Cancers)
  |  
PDF [297 KB, uploaded 7 August 2019]
  |  

Abstract

The diagnosis of neuroendocrine tumors (NETs) is a challenging task: Symptoms are rarely specific, and clinical manifestations are often evident only when metastases are already present. However, several bioactive substances secreted by NETs can be included for diagnostic, prognostic, and predictive purposes. Expression of these substances differs between different NETs according to the tumor hormone production. Gastroenteropancreatic (GEP) NETs originate from the diffuse neuroendocrine system of the gastrointestinal tract and pancreatic islets cells: These tumors may produce many non-specific and specific substances, such as chromogranin A, insulin, gastrin, glucagon, and serotonin, which shape the clinical manifestations of the NETs. To provide an up-to-date reference concerning the different biomarkers, as well as their main limitations, we reviewed and summarized existing literature. View Full-Text
Keywords: neuroendocrine tumors; biomarkers; gastroenteropancreatic tumors; prognostic markers; diagnosis neuroendocrine tumors; biomarkers; gastroenteropancreatic tumors; prognostic markers; diagnosis
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Sansone, A.; Lauretta, R.; Vottari, S.; Chiefari, A.; Barnabei, A.; Romanelli, F.; Appetecchia, M. Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors. Cancers 2019, 11, 1113.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top